UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Sensus Healthcare, Inc.

Common Stock

(Title of Class of Securities)

81728J109

(CUSIP Number)

July 25, 2016

 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

*On June 8, 2016, Sensus Healthcare, Inc. (the “Company”) closed its initial public offering of 2,300,000 units (the “Units”), trading under the symbol “SRTSU.” Each Unit consisted of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock. The Units sold in the Company’s initial public offering included 300,000 Units purchased by the underwriters pursuant to an over-allotment option that was exercised in full.

The Reporting Persons listed above filed a Schedule 13G on June 13, 2016 to report their beneficial ownership of an aggregate of 155,000 Units or 6.74% of the Units issued and outstanding as of June 8, 2016.

On July 21, 2016, the Company issued a press release announcing the separation of the Units, which occurred at market open on Monday, July 25, 2016. Following separation, the common stock and warrants included in the Units commenced trading separately under the symbols “SRTS” and “SRTSW,” respectively, and trading of the Units under the symbol “SRTSU” were suspended.

The shares of the Company’s common stock reported herein (the “Shares”) are held by RTW Master Fund, Ltd. (the “Master Fund”) and RTW Innovation Master Fund, Ltd., (the “Innovation Fund”), (collectively, the “Funds”), which are managed by RTW Investments, LLC (the “Adviser”). Roderick Wong is the Managing Member of the Adviser. The Adviser, in its capacity as the investment manager of the Funds, has the power to vote and direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 310,000 Shares or 2.44% of the shares of common stock issued and outstanding as of July 25, 2016. The beneficial ownership percentage reported herein is based on 12,700,000 shares of common stock issued and outstanding as of August 1, 2016, as reported on Bloomberg. This report shall not be deemed an admission that the Adviser or Roderick Wong is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Units reported herein except to the extent of the reporting person’s pecuniary interest therein.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit 1

Joint Filing Statement

Pursuant to Rule 13d-1(k)(1)

The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Units of Sensus Healthcare, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule13G.

This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.